Skip to content
2000
Volume 26, Issue 17
  • ISSN: 1389-2010
  • E-ISSN: 1873-4316

Abstract

Neurodegenerative diseases are regarded as gradual, incurable conditions with an insidious onset. Alzheimer’s disease (AD) and Parkinson’s disease (PD) are two of the most prevalent neurodegenerative diseases reported globally. Developing effective treatment strategies for neurodegenerative diseases has remained a primary objective and a huge challenge for researchers. The therapeutic medications that are now approved for the treatment of neurodegenerative diseases merely treat the symptoms; the underlying pathology is not addressed. Therefore, the emergence of novel disease-modifying therapeutic modalities such as immunotherapy has opened a new path in developing effective treatments for neurogenerative diseases. Compared to other types of subunit active vaccines, virus-like particles (VLPs) are considerably more immunogenic as they present dense and repetitive viral antigen epitopes on their surface, which can trigger both humoral and cell-mediated immune responses. They are also a much safer option than the traditional inactivated and live-attenuated vaccines since they are devoid of viral genomes and are, therefore, non-pathogenic and non-infectious. Researchers have turned their attention to VLPs as an active immunotherapy candidate for AD due to the lessons learned from the AN1792 trial. Studies have shown that they effectively induce anti-Aα-synuclein The technical limitations and potential difficulties associated with the future application of VLP-based vaccines in patients with neurodegenerative diseases have also been covered.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpb/10.2174/0113892010331763241002122854
2024-10-29
2026-02-23

  • From This Site

    /content/journals/cpb/10.2174/0113892010331763241002122854
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. KovacsG.G. Current concepts of neurodegenerative diseases.EMJ Neurol.201411101110.33590/emjneurol/10314777
     [Google Scholar]
  2. KovacsG. Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine.Int. J. Mol. Sci.201617218910.3390/ijms1702018926848654
     [Google Scholar]
  3. DuggerB.N. DicksonD.W. Pathology of Neurodegenerative Diseases.Cold Spring Harb. Perspect. Biol.201797a02803510.1101/cshperspect.a02803528062563
     [Google Scholar]
  4. SilvaM.V.F. LouresC.D.M.G. AlvesL.C.V. De SouzaL.C. BorgesK.B.G. CarvalhoM.D.G. Alzheimer’s disease: risk factors and potentially protective measures.J. Biomed. Sci.201926111110.1186/s12929‑019‑0524‑y
     [Google Scholar]
  5. ChuL.W. Alzheimer’s disease: early diagnosis and treatment.Hong Kong Med. J.201218322823722665688
     [Google Scholar]
  6. A.Armstrong R.; Richard, P.; Armstrong, A. Risk factors for Alzheimer’s disease.Folia Neuropathol.20195728710510.5114/fn.2019.8592931556570
     [Google Scholar]
  7. 2023 Alzheimer’s disease facts and figures.Alzheimers Dement.20231941598169510.1002/alz.1301636918389
     [Google Scholar]
  8. SimonD.K. TannerC.M. BrundinP. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology.Clin. Geriatr. Med.202036111210.1016/j.cger.2019.08.00231733690
     [Google Scholar]
  9. World Health Organization (WHO). Parkinson’s DiseaseAvailable from: https://www.who.int/news-room/fact-sheets/detail/parkinson-disease (accessed on 21-9-2024)
  10. VazM. SilvestreS. Alzheimer’s disease: Recent treatment strategies.Eur. J. Pharmacol.202088717355410.1016/j.ejphar.2020.17355432941929
     [Google Scholar]
  11. MaphisN.M. PeabodyJ. CrosseyE. Qß Virus-like particle-based vaccine induces robust immunity and protects against tauopathy.NPJ Vaccines20194113
     [Google Scholar]
  12. BouazzaouiA. AbdellatifA.A.H. Al-AllafF.A. BogariN.M. Al-DehlawiS. QariS.H. Strategies for Vaccination: Conventional Vaccine Approaches Versus New-Generation Strategies in Combination with Adjuvants.Pharmaceutics202113214010.3390/pharmaceutics1302014033499096
     [Google Scholar]
  13. U.S. Department of Health and Human Services Vaccine Types.Available from: https://www.hhs.gov/immunization/basics/types/index.html(accessed on 21-9-2024)
  14. IwasakiA. OmerS.B. Why and How Vaccines Work.Cell2020183229029510.1016/j.cell.2020.09.04033064982
     [Google Scholar]
  15. PetrovskyN. Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs.Drug Saf.201538111059107410.1007/s40264‑015‑0350‑426446142
     [Google Scholar]
  16. TomljenovicL. ShawC.A. Aluminum vaccine adjuvants: are they safe?Curr. Med. Chem.201118172630263710.2174/09298671179593374021568886
     [Google Scholar]
  17. MohsenM.O. ZhaL. Cabral-MirandaG. BachmannM.F. Major findings and recent advances in virus–like particle (VLP)-based vaccines.Semin. Immunol.20173412313210.1016/j.smim.2017.08.01428887001
     [Google Scholar]
  18. DonaldsonB. LateefZ. WalkerG.F. YoungS.L. WardV.K. Virus-like particle vaccines: immunology and formulation for clinical translation.Expert Rev. Vaccines201817983384910.1080/14760584.2018.151655230173619
     [Google Scholar]
  19. LomonossoffG.P. PonndorfD. Biotechnology Approaches to Modern Vaccine Design.Encyclopedia of Virology.Academic Press202110.1016/B978‑0‑12‑814515‑9.00067‑9
     [Google Scholar]
  20. ChenC.W. SaubiN. Joseph-MunnéJ. Design Concepts of Virus-Like Particle-Based HIV-1 Vaccines.Front. Immunol.20201157315710.3389/fimmu.2020.57315733117367
     [Google Scholar]
  21. DingX. LiuD. BoothG. GaoW. LuY. Virus‐Like Particle Engineering: From Rational Design to Versatile Applications.Biotechnol. J.2018135170032410.1002/biot.20170032429453861
     [Google Scholar]
  22. DengF. WangH. DengF. Advances and challenges in enveloped virus-like particle (VLP)-based vaccines.Journal of Immunological Sciences201822364110.29245/2578‑3009/2018/2.1118
     [Google Scholar]
  23. ZhangH. WeiW. ZhaoM. MaL. JiangX. PeiH. CaoY. LiH. Interaction between Aβ and Tau in the Pathogenesis of Alzheimer’s Disease.Int. J. Biol. Sci.20211792181219210.7150/ijbs.5707834239348
     [Google Scholar]
  24. TiwariS. AtluriV. KaushikA. YndartA. NairM. Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics.Int. J. Nanomedicine2019145541555410.2147/IJN.S20049031410002
     [Google Scholar]
  25. JankovicJ. TanE.K. Parkinson’s disease: etiopathogenesis and treatment.J. Neurol. Neurosurg. Psychiatry202091879580810.1136/jnnp‑2019‑32233832576618
     [Google Scholar]
  26. KouliA. TorsneyK.M. KuanW.L. Parkinson’s Disease: Pathogenesis and Clinical Aspects.Codon Publications2018
     [Google Scholar]
  27. AtriA. The Alzheimer’s Disease Clinical Spectrum.Med. Clin. North Am.2019103226329310.1016/j.mcna.2018.10.00930704681
     [Google Scholar]
  28. WellerJ. BudsonA. PorteliusE. ReddyH. Current understanding of Alzheimer’s disease diagnosis and treatment.F1000 Research.201871161
     [Google Scholar]
  29. LaneC.A. HardyJ. SchottJ.M. Alzheimer’s disease.Eur. J. Neurol.2018251597010.1111/ene.1343928872215
     [Google Scholar]
  30. CahillC. HuangX. Treatment options for motor and non-motor symptoms of parkinson’s disease.Biomolecules202111612
     [Google Scholar]
  31. BronzuoliM.R. IacominoA. SteardoL. ScuderiC. Targeting neuroinflammation in Alzheimer’s disease.J. Inflamm. Res.2016919920810.2147/JIR.S8695827843334
     [Google Scholar]
  32. DunnB. SteinP. CavazzoniP. Approval of Aducanumab for Alzheimer Disease—The FDA’s Perspective.JAMA Intern. Med.2021181101276127810.1001/jamainternmed.2021.460734254984
     [Google Scholar]
  33. LampteyR.N.L. ChaulagainB. TrivediR. GothwalA. LayekB. SinghJ. A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics.Int. J. Mol. Sci.2022233185110.3390/ijms2303185135163773
     [Google Scholar]
  34. CummingsJ. ApostolovaL. RabinoviciG.D. AtriA. AisenP. GreenbergS. HendrixS. SelkoeD. WeinerM. PetersenR.C. SallowayS. Lecanemab: Appropriate Use Recommendations.J. Prev. Alzheimers Dis.202310336237737357276
     [Google Scholar]
  35. Lecanemab in Early Alzheimer’s DiseaseN. Engl. J. Med.2023388142143
     [Google Scholar]
  36. MortadaI. FarahR. NabhaS. OjciusD.M. FaresY. AlmawiW.Y. SadierN.S. Immunotherapies for Neurodegenerative Diseases.Front. Neurol.20211265473910.3389/fneur.2021.65473934163421
     [Google Scholar]
  37. KwonS. IbaM. KimC. MasliahE. Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets.Neurotherapeutics202017393595410.1007/s13311‑020‑00853‑232347461
     [Google Scholar]
  38. WangZ. GaoG. DuanC. YangH. Progress of immunotherapy of anti-α-synuclein in Parkinson’s disease.Biomed. Pharmacother.201911510884310.1016/j.biopha.2019.10884331055236
     [Google Scholar]
  39. BayerA.J. BullockR. JonesR.W. WilkinsonD. PatersonK.R. JenkinsL. MillaisS.B. DonoghueS. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD.Neurology20056419410110.1212/01.WNL.0000148604.77591.6715642910
     [Google Scholar]
  40. Plascencia-VillaG. PerryG. Lessons from antiamyloid-β immunotherapies in Alzheimer’s disease.Handb. Clin. Neurol.202319326729110.1016/B978‑0‑323‑85555‑6.00019‑936803816
     [Google Scholar]
  41. ChackerianB. Virus-like particle based vaccines for Alzheimer disease.Hum. Vaccin.201061192693010.4161/hv.6.11.1265520864801
     [Google Scholar]
  42. OrgogozoJ.M. GilmanS. DartiguesJ.F. LaurentB. PuelM. KirbyL.C. JouannyP. DuboisB. EisnerL. FlitmanS. MichelB.F. BoadaM. FrankA. HockC. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization.Neurology2003611465410.1212/01.WNL.0000073623.84147.A812847155
     [Google Scholar]
  43. NicollJ.A.R. WilkinsonD. HolmesC. SteartP. MarkhamH. WellerR.O. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report.Nat. Med.20039444845210.1038/nm84012640446
     [Google Scholar]
  44. ZamoraE. HandisuryaA. Shafti-KeramatS. BorcheltD. RudowG. ConantK. CoxC. TroncosoJ.C. KirnbauerR. Papillomavirus-like particles are an effective platform for amyloid-β immunization in rabbits and transgenic mice.J. Immunol.200617742662267010.4049/jimmunol.177.4.266216888028
     [Google Scholar]
  45. BachP. TschäpeJ.A. KopietzF. BraunG. BaadeJ.K. WiederholdK.H. StaufenbielM. PrinzM. DellerT. KalinkeU. BuchholzC.J. MüllerU.C. Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice.J. Immunol.2009182127613762410.4049/jimmunol.080336619494285
     [Google Scholar]
  46. WiessnerC. WiederholdK.H. TissotA.C. FreyP. DannerS. JacobsonL.H. JenningsG.T. LüöndR. OrtmannR. ReichwaldJ. ZuriniM. MirA. BachmannM.F. StaufenbielM. The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects.J. Neurosci.201131259323933110.1523/JNEUROSCI.0293‑11.201121697382
     [Google Scholar]
  47. WinbladB. AndreasenN. MinthonL. FloesserA. ImbertG. DumortierT. MaguireR.P. BlennowK. LundmarkJ. StaufenbielM. OrgogozoJ.M. GrafA. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study.Lancet Neurol.201211759760410.1016/S1474‑4422(12)70140‑022677258
     [Google Scholar]
  48. VandenbergheR. RiviereM.E. CaputoA. SovagoJ. MaguireR.P. FarlowM. MarottaG. Sanchez-ValleR. ScheltensP. RyanJ.M. GrafA. Active Aβ immunotherapy CAD106 in Alzheimer’s disease: A phase 2b study.Alzheimers Dement. (N. Y.)201731102210.1016/j.trci.2016.12.00329067316
     [Google Scholar]
  49. FarlowM.R. AndreasenN. RiviereM.E. VostiarI. VitalitiA. SovagoJ. CaputoA. WinbladB. GrafA. Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease.Alzheimers Res. Ther.2015712310.1186/s13195‑015‑0108‑325918556
     [Google Scholar]
  50. Lopez LopezC. TariotP.N. CaputoA. LangbaumJ.B. LiuF. RiviereM.E. LangloisC. Rouzade-DominguezM.L. ZalesakM. HendrixS. ThomasR.G. VigliettaV. LenzR. RyanJ.M. GrafA. ReimanE.M. The Alzheimer’s Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer’s disease.Alzheimers Dement. (N. Y.)20195121622710.1016/j.trci.2019.02.00531211217
     [Google Scholar]
  51. Gonzalez-CastroR. Acero GalindoG. García SalcedoY. Uribe CamperoL. Vazquez PerezV. Carrillo-TrippM. GevorkianG. Gomez LimM.A. Plant-based chimeric HPV-virus-like particles bearing amyloid-β epitopes elicit antibodies able to recognize amyloid plaques in APP-tg mouse and Alzheimer’s disease brains.Inflammopharmacology201826381782710.1007/s10787‑017‑0408‑229094307
     [Google Scholar]
  52. ZeltinsA. WestJ. ZabelF. El TurabiA. BalkeI. HaasS. MaudrichM. StorniF. EngeroffP. JenningsG.T. KotechaA. StuartD.I. FoersterJ. BachmannM.F. Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer’s and cat allergy.NPJ Vaccines2017213010.1038/s41541‑017‑0030‑829263885
     [Google Scholar]
  53. JiM. XieX. LiuD. YuX. ZhangY. ZhangL.X. WangS. HuangY. LiuR. Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer’s disease and frontotemporal dementia.Alzheimers Res. Ther.20181015510.1186/s13195‑018‑0378‑729914543
     [Google Scholar]
  54. DoucetM. El-TurabiA. ZabelF. HunnB.H.M. Bengoa-VergnioryN. CiorochM. RammM. SmithA.M. GomesA.C. Cabral de MirandaG. Wade-MartinsR. BachmannM.F. Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles.PLoS One2017128e018184410.1371/journal.pone.018184428797124
     [Google Scholar]
  55. GuptaR. AroraK. RoyS.S. JosephA. RastogiR. AroraN.M. KunduP.K. Platforms, advances, and technical challenges in virus-like particles-based vaccines.Front. Immunol.202314112380510.3389/fimmu.2023.112380536845125
     [Google Scholar]
  56. LanN.T. KimH.J. HanH.J. LeeD.C. KangB.K. HanS.Y. MoonH. KimH.J. Stability of virus-like particles of red-spotted grouper nervous necrosis virus in the aqueous state, and the vaccine potential of lyophilized particles.Biologicals201851253110.1016/j.biologicals.2017.11.00229174141
     [Google Scholar]
  57. MarsianJ. FoxH. BaharM.W. KotechaA. FryE.E. StuartD.I. MacadamA.J. RowlandsD.J. LomonossoffG.P. Plant-made polio type 3 stabilized VLPs—a candidate synthetic polio vaccine.Nature. Communic.2017819
     [Google Scholar]
  58. TongT. D’AddabboA. XuJ. ChawlaH. NguyenA. OchoaP. CrispinM. BinleyJ.M. Impact of stabilizing mutations on the antigenic profile and glycosylation of membrane-expressed HIV-1 envelope glycoprotein.PLoS Pathog.2023198e101145210.1371/journal.ppat.101145237549185
     [Google Scholar]
  59. FiedlerJ.D. HigginsonC. HovlidM.L. KislukhinA.A. CastillejosA. ManzenriederF. CampbellM.G. VossN.R. PotterC.S. CarragherB. FinnM.G. Engineered mutations change the structure and stability of a virus-like particle.Biomacromolecules20121382339234810.1021/bm300590x22830650
     [Google Scholar]
  60. NooraeiS. BahrulolumH. HoseiniZ.S. KatalaniC. HajizadeA. EastonA.J. AhmadianG. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers.J. Nanobiotechnol.20211912710.1186/s12951‑021‑00806‑7
     [Google Scholar]
  61. CacabelosR. How plausible is an Alzheimer’s disease vaccine?Expert Opin. Drug Discov.20201511610.1080/17460441.2019.166732931526140
     [Google Scholar]
  62. YuH.J. DicksonS.P. WangP.N. ChiuM.J. HuangC.C. ChangC.C. LiuH. HendrixS.B. DodartJ.C. VermaA. WangC.Y. CummingsJ. Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase 2a study.EBioMedicine20239410466510.1016/j.ebiom.2023.10466537392597
     [Google Scholar]
  63. MohsenM.O. BachmannM.F. Virus-like particle vaccinology, from bench to bedside.Cellul. Molecul. Immunol.2022199993101110.1038/s41423‑022‑00897‑8
     [Google Scholar]
  64. SallowayS.P. SevingyJ. BudurK. PedersonJ.T. DeMattosR.B. Von RosenstielP. PaezA. EvansR. WeberC.J. HendrixJ.A. WorleyS. BainL.J. CarrilloM.C. Advancing combination therapy for Alzheimer’s disease.Alzheimers Dement. (N. Y.)202061e1207310.1002/trc2.1207333043108
     [Google Scholar]
  65. WiedermannU. Garner-SpitzerE. WagnerA. Primary vaccine failure to routine vaccines: Why and what to do?Hum. Vaccin. Immunother.201612123924310.1080/21645515.2015.109326326836329
     [Google Scholar]
  66. BrodyD.L. HoltzmanD.M. Active and passive immunotherapy for neurodegenerative disorders.Annu. Rev. Neurosci.200831117519310.1146/annurev.neuro.31.060407.12552918352830
     [Google Scholar]
  67. DavtyanH. HovakimyanA. Kiani ShabestariS. AntonyanT. CoburnM.A. ZagorskiK. ChailyanG. PetrushinaI. SvystunO. DanhashE. PetrovskyN. CribbsD.H. AgadjanyanM.G. Blurton-JonesM. GhochikyanA. Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice.Alzheimers Res. Ther.201911110710.1186/s13195‑019‑0556‑231847886
     [Google Scholar]
/content/journals/cpb/10.2174/0113892010331763241002122854
Loading

  • Article Type:     Review Article
Keyword(s): active immunotherapy; Alzheimer’s disease; Neurodegenerative diseases; Parkinson’s disease; therapeutic medications; virus-like particles-based vaccine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test